The transpeptidase (TP) activity of penicillin-binding proteins (PBPs), target of the β-lactam antibiotics, is a well-validated antibacterial drug target. The TP activity of PBP1b converts un-cross-linked peptidoglycan to the cross-linked form. Directly measuring TP activity is difficult because cross-linked and un-cross-linked peptidoglycan have very similar chromatographic properties. The authors report a microdilution plate method to directly measure the TP enzyme activity, uncoupled from the transglycosylase (TG), for detection of TP inhibitors. Escherichia coli membranes were incubated with 100 mM ampicillin, followed by removal of unbound ampicillin. The substrate for the TP, un-cross-linked peptidoglycan, was prepared by incubating these membranes with peptidoglycan sugar precursors, 1 of which was radiolabeled. Subsequently, solubilized PBP1b was added and TP activity assayed. The cross-linked peptidoglycan formed was monitored by addition of wheat germ agglutinin scintillation proximity assay beads plus N-laurylsarcosine, which selectively captures cross-linked peptidoglycan. The PBP1bcatalyzed activity was inhibited by penicillin G but not by cephalexin or cephradine, which have higher affinity for PBP1a. Moenomycin, a TG inhibitor, also inhibited TP activity. Because this is a true enzyme assay, it has the potential to detect novel, non-β-lactam TP inhibitors and could lead to the discovery of new antibacterial agents. (Journal of Biomolecular Screening
INTRODUCTION
R ESISTANCE TO CURRENT ANTIBIOTICS is increasing, and there is an urgent need for new antibiotics to treat drugresistant bacterial infections. Despite much effort by the pharmaceutical industry, there are very few new classes of antibiotics in the market. Many new enzyme targets have been explored, but all the drugs in the clinic today target the same few molecular processes that the natural product antibiotics target (e.g., DNA, protein, and cell wall synthesis). The success of many generations of β-lactam antibiotics, arguably the most successful class of antibiotics, warrants a relook at the target of these antibiotics in a target-based drug discovery program.
Peptidoglycan is unique to bacteria and is an essential structural component of the bacterial cell wall. It is a polymer of a repeating disaccharide-peptide unit, in which the pentapeptide chains attached to adjacent sugar molecules are cross-linked. The disaccharide unit is built on a lipid carrier at the cytoplasmic surface of the membrane giving rise to intermediates lipid I (undecaprenol-N-acetyl-muramylpentapeptide) and lipid II (undecraprenol-N-acetyl-muramylpentapeptide-N-acetylglucosamine; Fig. 1A) . The final stage of peptidoglycan synthesis is catalyzed at the periplasm by the penicillin-binding proteins (PBPs). The transglycosylase (TG) activity of the PBP polymerizes the disaccharide units, and the transpeptidase (TP) crosslinks the peptide chains ( Fig. 1A) . [1] [2] [3] Both TG and TP activities may be present in a single polypeptide, for example, the highmolecular-weight PBPs, PBP1a and 1b, of Escherichia coli. [4] [5] [6] [7] β-Lactam antibiotics covalently bind the PBPs and inactivate the TP activity. 4, 8 Although an attractive target for the development of new antimicrobials, the TP is extremely difficult to assay, especially in a format amenable to high-throughput screening (HTS). Its substrate, un-cross-linked peptidoglycan, is difficult to make, and in addition, it has very similar chromatographic properties to, and cannot be easily separated from, the product, cross-linked peptidoglycan. Both forms of peptidoglycan run at the origin of a paper chromatogram that is commonly used to separate peptidoglycan from its sugar precursors and lipid intermediates. 1, 9, 10 The degree of cross-linking of peptidoglycan is a direct measure of the transpeptidation reaction and can be measured by enzymatic degradation of peptidoglycan followed by analysis of the products by high-performance liquid chromatography or mass spectrometry. However, this procedure is laborious and needs large quantities of material, making it difficult to measure in large numbers of samples. 11 A far simpler assay is the monitoring of cross-linked peptidoglycan synthesis in whole cells permeabilized with ether, in which the cross-linked peptidoglycan formed is insoluble on boiling with detergent. This method has higher throughput than the above-mentioned assays, although it measures the TP as one of a series of enzyme reactions culminating in cross-linked peptidoglycan. [12] [13] [14] Another assay that has potential for higher throughput is the measure of UDP-N-acetylglucosamine (UDP-GlcNAc)-dependent release Step 1: Incubation of ampicillin pretreated membranes (membranes AMP ) with UDP-[ 3 H]GlcNAc and UDP-MurNAc(pp) results in synthesis of [ 3 H] un-cross-linked peptidoglycan (UnCL-PG) because the TP is inactivated; small quantities of cross-linked peptidoglycan may be formed. A parallel, a reaction in which UDP-MurNAc(pp) was omitted, is set up as a blank. One set of reactions is captured by wheat germ agglutinin-scintillation proximity assay (WGA-SPA) beads to analyze the quantity (Qty) of UnCL-PG plus cross-linked (CL-PG) peptidoglycan formed. A 2nd set is captured with WGA-SPA beads with N-laurylsarcosine (Sarkosyl) to measure the quantity of CL-PG formed. In step 2, a source of PBP1b is added to convert the UnCL-PG to cross-linked peptidoglycan, which is captured by WGA-SPA beads + N-laurylsarcosine.
of the terminal D-ala of N-acetylmuramyl-pentapeptide on formation of the transpeptide bond, 15, 16 although a microdilution plate assay for this has not been reported.
Because of the inherent difficulty in measuring the TP activity, many indirect assays have been used to screen for inhibitors of the TP, for example, hydrolysis of a synthetic peptide that mimics the peptidase activity that occurs concomitantly with cross-linking by the TP. [17] [18] [19] [20] Penicillin and other β-lactams bind covalently to the PBPs, and most assays for the TP use this principle. The most commonly used is a screen for agents that compete with a labeled β-lactam for binding to the PBP 21, 22 or cleavage of a chromogenic β-lactam on binding to the PBP. 23 However, these assays are not truly reflective of the enzyme activity, and in the light of widespread resistance to the β-lactams, a screen that detects new agents of the same class is of little value.
All 5 enzymes involved in stages 2 and 3 of peptidoglycan synthesis and also the lipid carrier substrate, undecaprenol phosphate, are membrane associated ( Fig. 1A) . Thus, by incubating E. coli membranes with the 2 UDP-linked sugar precursors, UDP-N-acetyl muramylpentapeptide (UDP-MurNAc-pp) and UDP-GlcNAc, the part of the peptidoglycan synthetic pathway shown in Figure 1A can be reproduced in a cell-free system. 10, 24 The 5 enzymes work in sequence to incorporate the sugars into cross-linked peptidoglycan, and if 1 of the sugar precursors is radio labeled (e.g., UDP-[ 3 H]GlcNAc), the resulting cross-linked peptidoglycan is radioactive and can be easily monitored. 25 Here we report a novel, homogenous, microplate method to directly measure the enzymatic activity of the peptidoglycan TP. It takes advantage of the mechanism of inhibition of the β-lactam antibiotics to inactivate the endogenous PBPs; these antibiotics inhibit the TP activity while not affecting the TG activity. The TP substrate, un-cross-linked peptidoglycan, was made in situ by incubation of ampicillin pretreated E. coli membranes with peptidoglycan sugar precursors UDP-N-acetylglucosamine (UDP-[ 3 H ]GlcNAc) and UDP-N-acetylmuramyl (pentapeptide) (UDP-MurNAc(pp)). Subsequently, a source of TP (i.e., PBP1b) was added, and the conversion of un-crosslinked peptidoglycan to cross-linked peptidoglycan was assayed by specific capture of the latter using wheat germ agglutininscintillation proximity assay (WGA-SPA) beads in the presence of N-laurylsarcosine. 25 The assay can be used to screen for inhibitors of the TP and has much higher throughput than earlier published assays.
MATERIALS AND METHODS

Materials
WGA-SPA beads (RPNQ0001, PVT beads) were from Amersham International plc (Buckinghamshire, UK). UDP-[ 3 H]-N-acetyl glucosamine was from NEN Dupont (Boston, MA). Most chemicals were from Sigma Chemical (St. Louis, MO). Flavomycin (moenomycin) was a gift from Hoechst (India). Antibiotic Medium 3 was from Difco Laboratories (Sparks, MD). Chromatography materials were from BioRad (Hercules, CA) or from Whatman (Florham Park, NJ). All strains were constructed in house. pBS96, a plasmid encoding E. coli PBP1b under the control of its own promoter, was obtained from B. Spratt.
Substrates
UDP-MurNAc(pp) was purified from Bacillus cereus 6A1 as described earlier. 10, 24 Briefly, UDP-MurNAc(pp) was purified from a hot water extract of the cells by gel filtration and ion exchange chromatography. The purification was monitored by sugar estimation, and its concentration was estimated from its absorbance at 262 nM using a molar extinction coefficient of 10,000.
Membrane-enzyme preparations
Membranes were used as a source of the enzymes involved in the late stages of peptidoglycan synthesis: MraY, MurG, lipid pyrophosphorylase, and the PBPs. Membranes were prepared from E. coli AMA1004 as described earlier. 10, 24 Briefly, the cells were suspended in 50 mM Tris-HCl pH 7.5, 0.1 mM MgCl 2 , and lysed in a French pressure cell. The supernatant of a low-speed centrifugation was centrifuged at 150,000g, and the pellet was washed once and used as the enzyme source. The quality of each membrane batch was monitored by measuring the peptidoglycan synthesized by different quantities of protein 24 as well as by the counts per minute (cpm) obtained in the blank reaction (see below).
Ampicillin-pretreated membranes. For the TP assay, membranes were treated with 100 mM ampicillin in HEPES-NaOH buffer pH 7.5 for 30 min at room temperature. Following this, the ampicillin was removed by centrifugation of the membranes at 150,000g in a Beckman table-top ultracentrifuge. The membranes were washed 3 times with 50 mM Tris-HCl pH 7.5, 0.1 mM MgCl 2 , resuspended in the same buffer, and stored in aliquots at -70° C; these are referred to as amp-membranes. Protein was estimated using Bradford Coommassie Plus reagent from Pierce Chemical Co. (Rockford, IL).
TP assay
The TP assay was performed in 2 steps. In the 1st step, the TP substrate, un-cross-linked peptidoglycan, was formed in situ in E. coli membranes, and in the 2nd step, PBP1b-mediated conversion of this to cross-linked peptidoglycan was monitored in a 96-well microdilution plate.
Step 1. For the 1st step, ampicillin-treated membranes (4 µg protein) were incubated for 20 min at 37°C with 25 µM UDP-MurNAc(pp) and 4.17 µM UDP-[ 3 H]GlcNAc (1.2 µCi) in a Screen for Peptidoglycan Transpeptidase Inhibitors in E. coli buffer of 50 mM HEPES-ammonia, pH 7.5, 10 mM MgCl 2 , in a total volume of 15 µl. A parallel "blank" reaction in which UDP-MurNAc(pp) was left out of the reaction was also set up; the difference between the radioactive product in the complete versus this blank (-UDP-MurNAc(pp)) reaction was taken as a measure of cross-linked peptidoglycan or total peptidoglycan synthesized, depending on the capture method used (Fig. 1B) . For every TP assay, 2 such sets of reactions were set up as a quality check and to monitor the products formed in step 1; 2 complete reactions were further processed to step 2, the assay of the TP.
One set (blank and complete reaction) was captured by WGA-SPA beads in the absence of detergent to monitor the total quantity of peptidoglycan synthesized (i.e., both un-cross-linked and cross-linked peptidoglycan). The 2nd set of blank and complete reactions was captured by WGA-SPA beads in the presence of 0.2% N-laurylsarcosine (Sarkosyl), to specifically measure the quantity of cross-linked peptidoglycan formed. A comparison of the radioactivity captured in the 2 methods (after subtraction of the corresponding blank) gives a rough estimate of what fraction of the total peptidoglycan formed in step 1 is cross-linked.
Step 2. The 2 complete step 1 reactions (+UDP-MurNAc(pp)) were further processed to assay the TP, with 1 of the reactions serving as an enzyme blank. To the contents of the step 1 reactions (15 µl) was further added 10 µl of a solution containing UDP-GlcNAc, DMSO, and a source of PBP1b in detergent (∼0.116 µg protein), such that the final concentration was 250 µM UDP-GlcNAc, 8% DMSO, 0.04% CHAPS, and 40 mM NaCl in a total volume of 25 µl; the reaction was incubated for 15 min (unless specified otherwise) at 37°C and stopped by addition of EDTA and WGA-SPA beads in the presence of 0.2% Nlaurylsarcosine. The blank used for this step was a parallel step 2 reaction in which no source of PBP1b was added; all other conditions remained the same.
If the quantity of cross-linked peptidoglycan formed by the exogenous PBP was to be measured, the parallel step 2 reaction without PBP was used as a blank, and this value was subtracted from the complete step 2 reaction.
In reactions with no exogenous source of PBP1b (in step 2), peptidoglycan was synthesized by the endogenous PBPs that had not been completely inactivated by the pretreatment with ampicillin. The quantity of peptidoglycan synthesized by endogenous PBP1b was calculated by subtracting the quantity of radioactivity formed in the step 1 complete reaction captured by WGA-SPA + 0.2% N-laurylsarcosine from that of the step 2 reaction without exogenously added PBP1b. If, however, this same blank is subtracted from the step 2 reaction conducted in the presence of exogenously added PBP1b, the quantity of cross-linked peptidoglycan formed will be a sum of the endogenous plus the exogenously added PBP1b.
Capture by WGA-SPA beads. All reactions were stopped by addition of 5 µl of 90 mM EDTA followed by immediate addition of 500 µg of WGA-SPA beads in HEPES-NaOH pH 7.5 to a final volume of 200 µl. In cases in which detergent was to be included, N-laurylsarcosine was added along with the beads so as to give a final concentration of 0.2% N-laurylsarcosine. Reactions were performed in 96-well flexible plates (1450-401) from Wallac (Finland). All reactions were carried out in duplicate. Radioactivity was measured directly in the same plate in a Microbeta Trilux 16 h after addition of the SPA beads. Because the efficiency of capture by the WGA-SPA beads is not known, results are expressed in cpm. For convenience in assaying a large number of reactions, step 1 can also be set up in an Eppendorf tube and transferred to a 96-well microdilution plate for step 2 reactions and for termination of step 1 and analysis of the step 1 products.
Graphs were plotted using Graphpad Prism software; error bars are used to indicate the standard error of the mean, but in some figures, these may not be obvious as they are smaller than the symbols. Where the purity of the starting material is not defined, compound concentrations are expressed in units other than micromoles.
Paper chromatography. For paper chromatography analysis of the products, after EDTA addition, 20 µl of the reaction was spotted on Whatman 3M paper, which was then dried and chromatographed overnight in isobutyric acid:1M ammonia (5:3 v/v). Peptidoglycan (both cross-linked and un-cross-linked) stays at the origin, which was cut out, and the radioactivity was measured in a liquid scintillation counter (using Optiphase HiSafe2 scintillation fluid; Wallac, Finland) after the paper had dried; lipid I and lipid II have an R f of ∼0.9. 9
Source of PBP1b
An earlier report from our laboratory has shown that a detergent extract of membranes overexpressing PBP1b can be used instead of purified PBP1b, giving activity similar to that of the pure protein. 26 Using the protocol described above, membranes were made from E. coli AMA1004, pBS96, that is, wild-type E. coli bearing a plasmid with the gene encoding PBP1b (ponB) under the control of its own promoter (B. Spratt, personal communication). The membranes were incubated for 60 min on ice with 1% CHAPS, 1 M NaCl, 100 mM Tris-HCl, pH 7.5, at a concentration of 5 mg/ml protein, followed by centrifugation at 150,000g for 15 min. The supernatant was used as a crude source of PBP1b. This was stored in aliquots at -70° C.
RESULTS
Step 1: Synthesis of un-cross-linked peptidoglycan in situ in E. coli membranes
Our aim was to make the TP substrate, un-cross-linked peptidoglycan, in situ in E. coli membranes. The β-lactams bind covalently to the PBPs and inactivate the TP but not the TG. Hence, we expected that in membranes pretreated with ampicillin or penicillin (amp-membranes), the TP activity alone of the endogenous PBPs would be inactivated and un-cross-linked peptidoglycan would be formed instead of cross-linked peptidoglycan. 24, 25 E. coli membranes were pretreated with ampicillin and incubated under conditions conducive to peptidoglycan synthesis (step 1 of the TP assay; Fig. 1B) . Reactions were stopped with EDTA at various times.
Peptidoglycan (both un-cross-linked and cross-linked) formation in these amp-membranes was monitored by capture with WGA-SPA beads (in the absence of detergent; Fig. 2A,  squares) . Under these conditions, we have shown that the beads capture total peptidoglycan and also lipid II, 25 but under these conditions, negligible lipid II was synthesized ( Table 1) . Hence, the values reflect total peptidoglycan made under these conditions.
To determine how much of this captured radioactivity was cross-linked peptidoglycan, a parallel reaction was captured with WGA-SPA beads with 0.2% N-laurylsarcosine ( Fig. 2A,  circles) ; under this condition, only the cross-linked peptidoglycan is measured. 25 The ratio of the quantity of radioactivity in the WGA-SPA + N-laurylsarcosine to the ratio of WGA-SPA-captured reactions is a rough estimate of the fraction of total peptidoglycan that is cross-linked ( Table 1) .
A significant quantity of radioactivity was captured by the WGA-SPA + N-laurylsarcosine reactions (i.e., cross-linked peptidoglycan). But the quantity of radioactivity captured by the WGA-SPA (absence of detergent -total peptidoglycan) was much larger than that captured by the WGA-SPA + Nlaurylsarcosine. Paper chromatography analysis indicated that no lipid II was formed under these conditions ( Table 2) . This indicates that indeed, as expected, un-cross-linked peptidoglycan was formed in the E. coli membranes that had been pretreated with ampicillin. However, a significant quantity of cross-linked peptidoglycan was also formed ( Table 1) .
The quantity of cross-linked peptidoglycan increased with step 1 incubation time ( Fig. 2A) : less than 30% of the total peptidoglycan was cross-linked at 20 min, whereas by 60 min, almost all of the peptidoglycan formed was cross-linked ( Table 2) . We think this background synthesis of cross-linked peptidoglycan in these amp-treated membranes was due to hydrolysis of the bound β-lactam off the PBP while washing the membranes free of ampicillin. In favor of this is the observation that the background increased gradually in ampicillin-treated membranes that were stored at -70° C; membranes were best used the day of preparation and were not stored for more than 2 weeks. In membranes stored for 3 months, even at 20 min, all of the peptidoglycan formed was cross-linked.
The other possibility is that the high quantity of cross-linked peptidoglycan formed in step 1 (i.e., high background) is due to incomplete inactivation of the PBPs. We think this is unlikely because pretreatment of the membranes with 20 mM or 100 mM ampicillin gave the same result: The background was not decreased by increasing the ampicillin concentration from 20 to 100 mM. However, for most experiments, the higher concentration of ampicillin was used. Penicillin pretreatment of membranes gave the same result as ampicillin pretreatment. Step 1: formation of the transpeptidase (TP) substrate, un-crosslinked peptidoglycan, in situ in Escherichia coli membranes. Membranes pretreated with ampicillin were incubated with UDP-N-acetylmuramylpentapeptide (UDP-MurNAc(pp)) and UDP-[ 3 H]GlcNAc for different times at 37°C. (A) Products formed in step 1: the reactions were stopped with EDTA, and the product was either captured by wheat germ agglutinin-scintillation proximity assay (WGA-SPA) beads (squares), which capture total peptidoglycan (un-cross-linked plus cross-linked peptidoglycan), or by WGA-SPA beads plus Nlaurylsarcosine (circles; WGA-SPA + S), which specifically capture cross-linked peptidoglycan (CL-PG). The blank for each capture condition was a similar reaction without UDP-MurNAc(pp). Activity (blank-subtracted count-per-minute values) for each capture condition is plotted as a function of time of step 1 incubation. The average blank for the WGA-SPA was 1404 cpm and 652 cpm for the WGA-SPA + S. (B) TP activity in step 2 as a function of step 1 incubation time, that is, quantity of CL-PG formed in step 2. At varying step 1 incubation times, the TP assay was started (i.e., a source of penicillin-binding protein 1b [PBP1b] was added and reactions were stopped and captured by WGA-SPA + 0.2% N-laurylsarcosine after 15 min at 37° C). The TP activity in step 2 (i.e., CL-PG) formed as a result of exogenously added PBP is plotted (i.e., the blank subtracted was a step 2 reaction without exogenous PBP ∼1865 cpm at 20 min).
Screen for Peptidoglycan Transpeptidase Inhibitors in E. coli
For the purpose of making the TP substrate in situ, the time of incubation had to be chosen such that a maximal quantity of un-cross-linked peptidoglycan was formed with minimal cross-linked peptidoglycan. These results suggested 20 min of incubation would be appropriate for step 1.
Step 2: TP assay
In a 2nd step, the TP was assayed. The radiolabel in the assay mix from step 1 was diluted by adding an ∼100-fold excess of unlabeled UDP-GlcNAc. This dilution of UDP-GlcNAc prevents synthesis of radioactive cross-linked peptidoglycan starting from the sugar precursors (which involves the activity of the 4 enzymes preceding the TP; Fig. 1A ) and also ensures that during step 2, only the labeled un-cross-linked peptidoglycan formed in step 1 is monitored for cross-linking by TP. Then, a source of PBP1b was added to allow the TP activity to be measured (i.e., cross-linking of the peptidoglycan to occur). Test compounds in DMSO were added at this stage. The reaction was stopped by addition of EDTA and WGA-SPA beads with Sarkosyl (Fig. 1B) .
In these assays, the source of PBP1b was a detergent extract of E. coli membranes overexpressing PBP1b on a plasmid. This is more convenient than having to purify the PBP when large numbers have to be screened. We have shown earlier that this can be used as a source of PBP1b and that it shows activity similar to purified PBP1b. 26 For testing the effect of step 1 incubation time on the TP assay, the step 1 incubation time was varied while monitoring the quantity of cross-linked peptidoglycan formed in a 15-min incubation time for step 2 (Fig. 2B) . From this result, too, it Reactions were captured by either wheat germ agglutinin-scintillation proximity assay (WGA-SPA) beads (total peptidoglycan) or WGA-SPA + N-laurylsarcosine (cross-linked peptidoglycan). The percentage ratio of radioactivity captured under the 2 conditions is shown (i.e., the fraction of peptidoglycan cross-linked as a percentage of total peptidoglycan). Multiple sets of step 1 and step 2 reactions were carried out in parallel, and products were either captured with wheat germ agglutinin-scintillation proximity assay (WGA-SPA), WGA-SPA + N-laurylsarcosine (Sarkosyl), or analyzed by paper chromatography. The TP assays (step 2 reactions) were performed by further incubating step 1 reactions with or without an external source of penicillin-binding protein (PBP) 1b. Penicillin G or moenomycin were added at step 2 where indicated. The blanks subtracted for calculation of the column activity in step 1 are the respective step 1 blank (no UDP MurNAc(pp)) reactions for WGA-SPA, WGA-SPA + Sarkosyl, or paper chromatography. The blanks subtracted for calculation of TP activity in step 2 are the step 1 complete reaction; these numbers are indicated in bold for WGA-SPA + Sarkosyl (3459 cpm) and paper chromatography (4248 cpm). a. The step 2 TP activity used for calculation of percentage inhibition by moenomycin, penicillin G, and nisin is represented in bold (2875 cpm).
appears that a 20-min incubation time in step 1 gives the best quantity of peptidoglycan cross-linking in step 2. This incubation time for step 1 was used in all further assays. While keeping the step 1 reaction time constant (20 min at 37° C), the incubation time for the TP assay (step 2) was varied by stopping it at different times (Fig. 3A) . Based on these results, a 15-min incubation time was chosen for the TP assay. The dotted line in Figure 3A represents total TP (i.e., cross-linking) activity in step 2. The solid line represents TP activity as a result of the exogenous PBP alone (i.e., the cpm obtained in a reaction in which no exogenous PBP was added was subtracted from the step 2 complete reaction). Presumably, the endogenous PBPs that have not been completely inactivated by pretreatment with ampicillin also contribute to cross-linking activity in step 2.
Subsequently, with a step 1 incubation time of 20 min and step 2 time of 15 min, the effect of varying the quantity of PBP1b (i.e., detergent extract of membranes) was studied. While varying the quantity of protein, the concentration of detergent and NaCl in the final reaction was kept constant because this affected the enzyme activity. The TP activity increased with increasing quantity of protein added. Approximately 0.116 µg protein equivalent of detergent extract of the PBP1b overexpressing membranes was used for further assays (Fig. 3B) .
Effect of inhibitors
The effect of inhibitors on the TP assay was studied by adding the inhibitors at step 2, along with the UDP-GlcNAc and exogenous source of PBP1b. As expected, penicillin inhibited the TP with an IC 50 of ∼5 to 10 µM (Fig. 3C) . Ampicillin, too, inhibited the TP with a similar IC 50 . Cephaloridine and cefsulodin also inhibited the TP assay (>90% inhibition at 100 µM), but cephalexin and cephradine, β-lactam antibiotics with greater affinity for PBP1a, 26, 27 did not inhibit the TP (<20% inhibition at 100 µM). This was expected in the background of our previous results, that under similar conditions in wild-type E. coli membranes, cephalexin and cephradine do not inhibit peptidoglycan synthesis. 25 It also confirmed that we were primarily measuring the TP activity of PBP1b in this detergent extract. Surprisingly, moenomycin, hitherto considered an inhibitor of the TG, inhibited the TP with an IC 50 of ∼11 nM (Fig. 3D) , a concentration similar to that at which it inhibits the TG or the entire pathway of peptidoglycan synthesis. 1, 26 Nisin, an inhibitor of MurG, which was recently reported to inhibit the TG, 26 also inhibited the TP, with an IC 50 between 1 and 17 µg/ml (Fig. 3E) .
Validation by paper chromatography
Inhibition of the TP by moenomycin, hitherto considered a TG inhibitor, was surprising. To confirm this and also to analyze the products formed in the TP assay, the reactions were analyzed by paper chromatography in parallel with the SPA in the same experiment ( Table 2) . Negligible lipid II was formed, as evidenced by the counts at the solvent front (R f ∼0.9). However, peptidoglycan was indeed formed in step 1, as seen by counts at the origin of the paper chromatogram. The paper chromatogram cannot distinguish cross-linked from un-cross-linked peptidoglycan. But part of the peptidoglycan must be crosslinked because it was captured by WGA-SPA beads + Nlaurylsarcosine ( Table 2 ). In step 1, the WGA-SPA captured almost twice as much radiolabel as the WGA-SPA + Nlaurylsarcosine did, indicating that a large percentage (∼50%) of the peptidoglycan must have been un-cross-linked.
During step 2, the radioactivity at the origin of the paper chromatogram did not change significantly from that in step 1 (the counts varied by ∼10%), indicating that the total quantity of peptidoglycan (un-cross-linked plus cross-linked) did not change during step 2. Yet the quantity of WGA-SPA + Nlaurylsarcosine-captured material (i.e., cross-linked peptidoglycan) increased significantly. We attribute this change to conversion of some of the un-cross-linked peptidoglycan formed in step 1 to cross-linked peptidoglycan by the TP in step 2. As seen in Table 2 , even in the absence of exogenously added PBP, crosslinking did occur, but the conversion was approximately 2.5 times greater in the presence of exogenous PBP.
The inhibitors penicillin and moenomycin, as expected, caused insignificant change in the quantity of radioactivity at the origin of the paper chromatogram, indicating that the total quantity of peptidoglycan was not changed by these inhibitors. This is in contrast to cases of inhibition of the TG when radioactivity at the origin of the paper chromatogram decreased. 24, 26 However, penicillin (300 µM) caused complete inhibition of TP activity as seen in the WGA-SPA + N-laurylsarcosine counts; it is expected that penicillin, a TP inhibitor, would completely inhibit the crosslinking reaction. The same profile was obtained with moenomycin, a TG inhibitor: complete inhibition of the cross-linking reaction (i.e., WGA-SPA + N-laurylsarcosine), confirming it as TP inhibitor. The cross-linking caused by both the endogenously and exogenously added PBP was inhibited by both penicillin and moenomycin. Nisin also showed the same profile as penicillin and moenomycin, confirming TP inhibition; however, in this experiment, inhibition was not total.
DISCUSSION
In the 2-step TP assay described here, the quantity of crosslinked peptidoglycan formed in step 1 (background) was quite high compared to the quantity made during step 2, the TP assay. Despite the high background, because the activity was dependent on time and the quantity of protein and was inhibited by inhibitors of PBP1b but not those of PBP1a, the assay is shown to measure TP enzyme activity and can be used to screen for novel inhibitors of the TP.
This background activity must be due to activity of the PBPs present in the membrane preparation that have not been inactivated by pretreatment with the β-lactam. We have primarily used ampicillin and penicillin to inactivate the endogenous PBPs, but other penicillins or cephalosporins should be as effective. We think the high background is a result of hydrolysis of the PBP-bound β-lactam, so a β-lactam that is less susceptible to hydrolysis may be more effective.
Another reason for the high quantity of cross-linked peptidoglycan made in step 1 (background) could be that the cpm observed does not reflect the number of cross-links formed. It could well be that the number of cross-links formed (i.e., degree of transpeptidation) is much greater in step 2 than that formed in step 1 and that if we were truly measuring the number of crosslinks, the background would not be high. In peptidoglycan, not every peptide chain is cross-linked. 28 In this assay, the Nacetylglucosamine is radiolabeled, and thus, the radioactivity captured by the WGA-SPA + N-laurylsarcosine is reflective of the number of N-acetylglucosamine residues present in the crosslinked peptidoglycan, not the number of cross-links, because there is not a 1:1 relationship between the 2. The number of crosslinks must be estimated by other means (e.g., the degree of crosslinking or by measuring the quantity of D-ala released during step 1 v. step 2 to confirm this hypothesis); comparison of the number of cross-links with the cpm obtained in the WGA-SPA + Sarkosylcaptured reactions may explain the high background in step 1.
A hypothesis present in the literature of how peptidoglycan is synthesized is that 3 polymer chains of peptidoglycan are first formed, and these are subsequently attached to preexisting peptidoglycan by the transpeptidation reaction. 13, [29] [30] [31] Our earlier observation that the WGA-SPA + N-laurylsarcosine does not capture un-cross-linked peptidoglycan fits the hypothesis that peptidoglycan chains are attached to the preexisting cell wall by the transpeptidation reaction and that only such peptidoglycan units are measured under these SPA conditions. 25 This hypothesis could also explain the high background in the assay (e.g., a single cross-link in the 1st step may cause capture of a large number of radioactive N-acetylglucosamine residues, whereas an additional 5 cross-links in step 2 may not capture 5 times more radioactivity; Fig. 4) . It thus appears that the potency of an inhibitor may be underestimated.
The quantity of radiolabel used in this assay is quite high and could make the cost a limitation for HTS. A solution could be the use of an HTS-compatible pathway screen 24 to select peptidoglycan pathway inhibitors from a library, followed by this assay as a secondary screen to pick out the TP inhibitors. Rational drug design is also an option for obtaining novel TP inhibitors, and this assay could be used to test and characterize such inhibitors.
The assay as described measures the TP activity predominant under these conditions, that of PBP1b. Although we have demonstrated only the TP activity of PBP1b of E. coli, we think the assay could be used to assay the TP activity of PBP1a if pure PBP1a, or solubilized membrane of a strain overexpressing PBP1a, is used. 26 It should, in principle, also be possible to study the TP activity of PBPs from other bacterial species.
Having a microplate-based assay makes it easy to test inhibitors. This revealed, to our surprise, that inhibitors of some of the other enzymes in the peptidoglycan pathway also inhibit TP (e.g., moenomycin, nisin). Because the TP activity is difficult to assay, these have most likely not previously been tested on this enzyme. It illustrates that despite the limitations, novel inhibitors of TP can be detected. The fact that the assay measures enzyme activity of TP will be an advantage in the search for novel antibacterial agents.
